The pathophysiology of bronchiectasis

Paul T King, Paul T King

Abstract

Bronchiectasis is defined by permanent and abnormal widening of the bronchi. This process occurs in the context of chronic airway infection and inflammation. It is usually diagnosed using computed tomography scanning to visualize the larger bronchi. Bronchiectasis is also characterized by mild to moderate airflow obstruction. This review will describe the pathophysiology of noncystic fibrosis bronchiectasis. Studies have demonstrated that the small airways in bronchiectasis are obstructed from an inflammatory infiltrate in the wall. As most of the bronchial tree is composed of small airways, the net effect is obstruction. The bronchial wall is typically thickened by an inflammatory infiltrate of lymphocytes and macrophages which may form lymphoid follicles. It has recently been demonstrated that patients with bronchiectasis have a progressive decline in lung function. There are a large number of etiologic risk factors associated with bronchiectasis. As there is generally a long-term retrospective history, it may be difficult to determine the exact role of such factors in the pathogenesis. Extremes of age and smoking/chronic obstructive pulmonary disease may be important considerations. There are a variety of different pathogens involved in bronchiectasis, but a common finding despite the presence of purulent sputum is failure to identify any pathogenic microorganisms. The bacterial flora appears to change with progression of disease.

Keywords: bronchiectasis; inflammation; obstructive lung disease; pathology; pathophysiology.

Figures

Figure 1
Figure 1
HRCT examples of Reid’s three forms of bronchiectasis: A) tubular B), varicose, and C) cystic. Abbreviation: HRCT, high-resolution computed tomography.
Figure 2
Figure 2
Pathologic changes in follicular bronchiectasis as described by Whitwell. A) The first process involves infection of the small airways. B) This leads to the release of inflammatory mediators such as proteases which damage the large airways resulting in bronchial dilation and bronchiectasis. C) Infection drives progressive inflammation in the small airways which become thicker from a combination of cell-mediated inflammatory infiltrate and lymphoid follicles resulting in obstruction. D) The final process involves the spread of inflammation beyond the airways resulting in interstitial pneumonia.
Figure 3
Figure 3
Pathologic process in the right middle lobe with mycobacterial infection. A) Infection causes enlargement of peribronchial lymph nodes resulting in obstruction. B) The obstruction results in bronchiectasis that persists when the nodes return to normal size.
Figure 4
Figure 4
Change in severity of symptoms over time in those with childhood-onset bronchiectasis. A common finding in subjects whose symptoms began in childhood is improvement in late adolescence and then deterioration again from about the age of 50 years.

References

    1. Barker AF. Bronchiectasis. N Engl J Med. 2002;346:1383–1393.
    1. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006;100:2183–2189.
    1. McGuinness G, Naidich DP. CT of airways disease and bronchiectasis. Radiol Clin North Am. 2002;40:1–19.
    1. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;4:205–209.
    1. O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55:635–642.
    1. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:400–407.
    1. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995;108:955–961.
    1. Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Validation of the St. George’s Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997;156:536–541.
    1. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998;113:1329–1334.
    1. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162:1277–1284.
    1. Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med. 2001;164:1628–1632.
    1. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallagher M, Holmes PW. Outcome in Adult Bronchiectasis. COPD: Journal of Chronic Obstructive Pulmonary Diseases. 2005;2:27–34.
    1. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thoraxi. 2006;61:414–418.
    1. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565–1572.
    1. Cole PJ. Inflammation: a two-edged sword – the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6–15.
    1. Reid L. Reduction in bronchial subdivisions in bronchiectasis. Thorax. 1950;5:223–247.
    1. Whitwell F. A study of the pathology and pathogenesis of bronchiectasis. Thorax. 1952;7:213–219.
    1. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–2653.
    1. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J. 2008;31:396–406.
    1. Eller J, Lapa e Silva JR, Poulter LW, Lode H, Cole PJ. Cells and cytokines in chronic bronchial infection. Ann N Y Acad Sci. 1994;725:331–345.
    1. Loukides S, Bouros D, Papatheodorou G, Lachanis S, Panagou P, Siafakas NM. Exhaled H2O2 in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest. 2002;121:81–87.
    1. Khair OA, Davies RJ, Devalia JL. Bacterial-induced release of inflammatory mediators by bronchial epithelial cells. Eur Respir J. 1996;9:1913–1922.
    1. Zheng L, Tipoe G, Lam WK, et al. Up-regulation of circulating adhesion molecules in bronchiectasis. Eur Respir J. 2000;16:691–696.
    1. Lapa e Silva JR, Guerreiro D, Noble B, Poulter LW, Cole PJ. Immunopathology of experimental bronchiectasis. Am J Respir Cell Mol Biol. 1989;1:297–304.
    1. Gaga M, Bentley AM, Humbert M, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax. 1998;53:685–691.
    1. Loubeyre P, Paret M, Revel D, Wiesendanger T, Brune J. Thin-section CT detection of emphysema associated with bronchiectasis and correlation with pulmonary function tests. Chest. 1996;109:360–365.
    1. Field E. Bronchiectasis: a long-term follow-up of medical and surgical cases from childhood. Arch Dis Child. 1961;36:587–603.
    1. Graham EA, Burford TH, Mayer TH. Middle lobe syndrome. Postgrad Med. 1948;4:29.
    1. Brock RC. Post-tuberculosis broncho-stenosis and bronchiectasis of the middle lobe. Thorax. 1950;5:5–11.
    1. Fretheim B. The so-called middle lobe syndrome. Thorax. 1952;7:156–158.
    1. Albo RJ, Grimes OF. The middle lobe syndrome: a clinical study. Dis Chest. 1966;50:509–518.
    1. Bombarda S, Figueiredo CM, Seiscento M, Terra Filho M. Pulmonary tuberculosis: tomographic evaluation in the active and post-treatment phases. Sao Paulo Med J. 2003;121:198–202.
    1. Bertelsen S, Struve-Christensen E, Aasted A, Sparup J. Isolated middle lobe atelectasis: aetiology, pathogenesis, and treatment of the so-called middle lobe syndrome. Thorax. 1980;35:449–452.
    1. Levin DL. Radiology of pulmonary Mycobacterium avium-intracellulare complex. Clin Chest Med. 2002;23:603–612.
    1. King PT, Holdsworth S, Farmer MW, Freezer N, Villanueva E, Holmes P. Phenotypes of bronchiectasis: onset of productive cough in childhood and adulthood. COPD. 2009;6:130–136.
    1. King P. Bronchiectasis and chronic rhinosinusitis. Respir Med CME. 2008;1:284–285.
    1. Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax. 2000;55:198–204.
    1. Lynch DA, Simone PM, Fox MA, Bucher BL, Heinig MJ. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr. 1995;19:353–360.
    1. Fujita J. Radiological findings of non-tuberculous mycobacteria respiratory infection. Kekkaku. 2003;78:557–561.
    1. Bush A, Chodhari R, Collins N, et al. Primary ciliary dyskinesia: current state of the art. Arch Dis Child. 2007;92:1136–1140.
    1. Escudier E, Duquesnoy P, Papon JF, Amselem S. Ciliary defects and genetics of primary ciliary dyskinesia. Paediatr Respir Rev. 2009;10:51–54.
    1. Hogg C. Primary ciliary dyskinesia: when to suspect the diagnosis and how to confirm it. Paediatr Respir Rev. 2009;10:44–50.
    1. Omran H, Kobayashi D, Olbrich H, et al. Ktu/PF13 is required for cytoplasmic pre-assembly of axonemal dyneins. Nature. 2008;456:611–616.
    1. Colantonio JR, Vermot J, Wu D, et al. The dynein regulatory complex is required for ciliary motility and otolith biogenesis in the inner ear. Nature. 2009;457:205–209.
    1. Friedman KJ, Teichtahl H, De Kretser DM, et al. Screening Young syndrome patients for CFTR mutations. Am J Respir Crit Care Med. 1995;152:1353–1357.
    1. Marostica PJ, Fischer GB. Non-cystic-fibrosis bronchiectasis: a perspective from South America. Paediatr Respir Rev. 2006;7:275–280.
    1. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis. 2004;8:691–702.
    1. Sethi GR, Batra V. Bronchiectasis: causes and management. Indian J Pediatr. 2000;67:133–139.
    1. Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration. 2005;72:233–238.
    1. Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol. 2000;29:182–187.
    1. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in indigenous children in remote Australian communities. Med J Aust. 2002;177:200–204.
    1. Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis “too high” for a developed country. Arch Dis Child. 2005;90:737–740.
    1. Chinen J, Shearer WT. 6. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2008;121:S388–S392. quiz S417.
    1. English BK, Schroeder HW, Wilson CB. Immaturity of the fetal and neonatal immune system. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW, editors. Clinical Immunology, Principles and Practice. London, UK: Mosby; 2001. pp. 40.10–40.41.
    1. Weksler ME, Szabo P. Aging and the immune system. In: Rich RR, Fleicher TA, Shearer WT, Kotzin BL, Schroeder HW, editors. Clinical Immunology; Principles and Practice. London, UK: Mosby; 2001. pp. 41.41–48.
    1. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax. 2006;61:1043–1047.
    1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269–280.
    1. Wagner RB, Johnston MR. Middle lobe syndrome. Ann Thorac Surg. 1983;35:679–686.
    1. De Boeck K, Willems T, Van Gysel D, Corbeel L, Eeckels R. Outcome after right middle lobe syndrome. Chest. 1995;108:150–152.
    1. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996;335:1941–1949.
    1. Cortet B, Flipo RM, Remy-Jardin M, et al. Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis. 1995;54:815–819.
    1. Hassan WU, Keaney NP, Holland CD, Kelly CA. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis. 1995;54:308–310.
    1. Larche MJ. A short review of the pathogenesis of Sjogren’s syndrome. Autoimmun Rev. 2006;5:132–135.
    1. King P. Churgh-Strauss syndrome and bronchiectasis. Respir Med Extra. 2007;3:26–28.
    1. Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest. 2007;131:524–532.
    1. Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176:1215–1221.
    1. Roberts DE, Cole P. Use of selective media in bacteriological investigation of patients with chronic suppurative respiratory infection. Lancet. 1980;1:796–797.
    1. Pang J, Chan HS, Sung JY. Prevalence of asthma, atopy, and bronchial hyperreactivity in bronchiectasis: a controlled study. Thorax. 1989;44:948–951.
    1. Ho PL, Chan KN, Ip MS, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest. 1998;114:1594–1598.
    1. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57:15–19.
    1. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007;101:1633–1638.
    1. Klingman KL, Pye A, Murphy TF, Hill SL. Dynamics of respiratory tract colonization by Branhamella catarrhalis in bronchiectasis. Am J Respir Crit Care Med. 1995;152:1072–1078.
    1. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465–471.
    1. Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax. 2005;60:1045–1051.
    1. Fowler SJ, French J, Screaton NJ, et al. Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics. Eur Respir J. 2006;28:1204–1210.
    1. Becroft DM. Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young children. J Clin Pathol. 1971;24:72–82.
    1. Pang G, Clancy R, Cong M, Ortega M, Zhigang R, Reeves G. Influenza virus inhibits lysozyme secretion by sputum neutrophils in subjects with chronic bronchial sepsis. Am J Respir Crit Care Med. 2000;161:718–722.
    1. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618–1623.
    1. Wilson R, Cole PJ. The effect of bacterial products on ciliary function. Am Rev Respir Dis. 1988;138:S49–S53.
    1. Moller LV, Timens W, van der Bij W, et al. Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease. Am J Respir Crit Care Med. 1998;157:950–956.
    1. Bandi V, Apicella MA, Mason E, et al. Nontypeable haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med. 2001;164:2114–2119.
    1. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care. 2009;54:628–640.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel